Serum Levels of MMP9 and MMP2 in Patients with Oral Squamous Cell Carcinoma

  • Lotfi, Alireza (Department of Otorhinolaryngology, Tabriz University of Medical Sciences) ;
  • Mohammadi, Ghodrat (Department of Otorhinolaryngology, Tabriz University of Medical Sciences) ;
  • Tavassoli, Atena (Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • mousaviagdas, Mehrnoosh (Department of Otorhinolaryngology, Tabriz University of Medical Sciences) ;
  • Chavoshi, Hadi (Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Saniee, Lale (Hematology and Oncology Research Center, Tabriz University of Medical Sciences)
  • Published : 2015.03.09


Background: Squamous cell carcinoma (SCC) is the most common cancer in the oral area. Matrix metalloproteinases (MMPs) and especially MMP-2 and MMP-9 are increased in malignancy and lymph node involvement in oral SCCs. We aimed to evaluate the serum levels of MMP-2 and MMP-9 in patients with oral SCC compared to normal subjects and their relation with clinicopathological findings. Materials and Methods: In this case control study, 20 patients with oral SCC and 20 healthy subjects were included and serum levels of MMP-2 and MMP-9 were compared between groups. Also, the correlation between these markers with clinicopathological findings including grade (T) and node (N) were evaluated. Results: Patients with oral SCC had significantly higher serum levels of MMP-2 (p=0.01) and MMP-9 (p<0.001) compared to healthy subjects. With increase in grade T, MMP-2 was significantly increased (p=0.001), but in the MMP-9 case this was not significant (p=0.27). The levels of MMP-2 (p=0.002) and MMP-9 (p=0.01) in cases with lymph node involvement and that of MMP-2 in subjects with smoking history (p=0.001) were significantly high. There was significantly positive correlation between MMP-2 with grade T tumor (r=0.598, p=0.005), lymph node involvement (r=0.737, p<0.001) and smoking (r=0.674, p=0.001) and also between MMP-9 and lymph node involvement (r=0.474, p=0.03). Conclusions: Both markers are significantly increased in oral SCC compared to healthy subjects. However, MMP-2 was better for evaluating lymph node involvement and tumor grade.


Squamous cell carcinoma;matrix metalloproteinase 2;matrix metalloproteinase 9;grade


Grant : which was a part of Otorhinolaryngology sub-specialty thesis no. 92/3-5/5

Supported by : Tabriz University of Medical Sciences


  1. Abbasi MM, Jahanban-Esfahlan R, Monfaredan A, et al (2014). Oral and IV dosages of doxorubicin-methotrexate loadednanoparticles inhibit progression of oral cancer by downregulation of matrix methaloproteinase 2 expression in vivo. Asian Pac J Cancer Prev, 15, 10705-11.
  2. Bedal KB, Grassel S, Oefner PJ, et al (2014). Collagen XVI induces expression of MMP9 via modulation of AP-1 transcription factors and facilitates invasion of oral squamous cell carcinoma. PLoS ONE, 9, 86777.
  3. Di Domenico M, Ricciardi C, Fusco A, Pierantoni GM (2011). Anti-VEGF therapy in breast and lung mouse models of cancers. J Biomed Biotechnol, 2011, 947928.
  4. de Vicente JC, Fresno MF, Villalain L, et al (2005). Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol, 41, 283-93.
  5. Elahi M, Rakhshan V, Ghasemian NT, Moshref M (2012). Prognostic value of transforming growth factor beta 1 [TGF-${\beta}1$] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers, 17, 21-7.
  6. Erdem NF, Carlson ER, Gerard DA, Ichiki AT (2007). Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg, 65, 1725-33.
  7. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004). Matrix metalloproteinases in cancer: from new functions to improved inhabitation strategies. Int J Dev Biol, 48, 411-24.
  8. Forsyth PA, Wong H, Laing TD, et al (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79, 1828-35.
  9. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One, 3, 1774.
  10. Hong Q, Jun T, Lei J, Xiling J, Tamamura R (2006). Expression and clinical significance of matrix metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell carcinoma. J Hard Tissue Biol, 15, 54-60.
  11. Johnson NW, Jayasekara P, Amarasinghe AA (2011). Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontology, 57, 19-37.
  12. Katayama A, Bandoh N, Kishibe K, et al (2004). Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res, 10, 634-40.
  13. Knapinska A, Fields GB (2012). Chemical biology for understanding matrix metalloproteinase function. Chembiochem, 13, 2002-20.
  14. Kondakova IV, Klisho EV, savenkova OV (2008). Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis. Biomed Khim, 54, 555-60.
  15. Li M, Wang Z, Xing Y, et al (2014). A Multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma. Iran Red Crescent Med J, 16, 13185.
  16. Liu G, Li J, Li Z, Chen X (2001). The effects of MMPs and TIMPs on the metastasis of oral squamous cell carcinoma to neck lymph nodes. Hua Xi Kou Qiang Yi Xue Za Zhi, 19, 216-8, 224 (in Chinese).
  17. Makinen LK, Hayry V, Atula T, et al (2012). Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J Oral Pathol Med, 41, 394-9.
  18. Mardani M, Andisheh-Tadbir A, Khademi B, Biparva P, Malekzadeh M (2014). Serum level of matrix metalloproteinase-9 in patients with salivary gland tumor. J Dent Shiraz Univ Med Sci, 15, 199-203.
  19. Mohtasham N, Babakoohi S, Shiva A, et al (2013). Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract, 209, 110-4.
  20. Monteiro-Amado F, Castro-Silva II, Lima CJ, et al (2013). Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth. Braz Dent J, 24, 3-9.
  21. Nikkola J, Vihinen P, Vuoristo MS, et al (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res, 11, 5158-66.
  22. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE (2012). Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent, 4, 297-301.
  23. Rosenthal EL, Matrisian LM (2006). Matrix metalloproteinases in head and neck cancers. Head Neck, 10, 639-48.
  24. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A (2008). Salivary concentration of INF6, TNFa, IL1a, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal, 13, 292-5.
  25. Singh RD, Haridas N, Patel JB, et al (2010). Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem, 25, 250-9.
  26. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG (2012). Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol, 181, 1895-9.
  27. Tadbir AA, Purshahidi S, Ebrahimi H (2012). Serum level of MMP-3 in patients with oral squamous cell carcinoma-lack association with clinico-pathological features. Asian Pac J Cancer Prev, 13, 4545-8.
  28. Vilen ST, Salo T, Sorsa T, Nyberg P (2013). Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Scientific World Journal, 2013, 920595.
  29. Wang G, Wang W, Zhou J, Yang X (2013). Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark, 13, 21-8.
  30. Wu ZS, Wu Q, Yang JH, et al (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6.
  31. Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085-91.
  32. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res, 20, 1311-6.
  33. Zhang J, Yin L, Wu J, et al (2014). Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med, 8, 175-80.

Cited by

  1. A systematic approach to prioritize drug targets using machine learning, a molecular descriptor-based classification model, and high-throughput screening of plant derived molecules: a case study in oral cancer vol.11, pp.12, 2015,
  2. Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Significance vol.16, pp.15, 2015,
  3. Comparison of Serum Fucose Levels in Leukoplakia and Oral Cancer Patients vol.16, pp.17, 2015,
  4. Cigarette smoke extract induces oral squamous cell carcinoma cell invasion in a receptor for advanced glycation end-products-dependent manner vol.126, pp.1, 2017,